Kirk M. Druey, M.D.

Senior Investigator

Molecular Signal Transduction Section

NIAID/DIR

4 Memorial Drive, Room 228B
Bethesda, MD 20814

301-435-8875

kdruey@nih.gov

Research Topics

The primary focus of our laboratory is to understand the signaling pathways evoked by G-protein-coupled receptors (GPCRs) and the role of the dysregulated GPCR signaling in the pathogenesis of asthma and allergic disease. Although therapeutic agents targeting GPCRs have long been used to treat asthma and allergies, much remains unknown regarding pathomechanisms associated with their downstream signaling pathways. Our goals are to identify specific genetic and molecular abnormalities involved in two distinct processes: 1) airway contraction and relaxation and 2) vascular permeability. Our studies of asthma utilize mouse models of allergen-induced airway inflammation, which have uncovered novel therapeutic targets for specific asthma endotypes. The second area of focus is a rare and highly unusual disorder, the Systemic Capillary Leak Syndrome. This disease is characterized by reversible episodes of hypovolemia, hypotensive shock, and anasarca, which are thought to be a result of transient endothelial hyper-permeability.

Biography

Dr. Druey obtained his M.D. from Rush Medical College in Chicago, Illinois. In 1992, following a residency in internal medicine at The New York Hospital/Cornell Medical Cent‚Äčer, Dr. Druey became a postdoctoral fellow in the NIAID Laboratory of Immunoregulation. He joined the Laboratory of Allergic Diseases in 1997 to become chief of the Molecular Signal Transduction Section.

Selected Publications

  1. Chinn IK, Xie Z, Chan EC, Nagata BM, Koval A, Chen WS, Zhang F, Ganesan S, Hong DN, Suzuki M, Nardone G, Moore IN, Katanaev VL, Balazs AE, Liu C, Lupski JR, Orange JS, Druey KM. Short stature and combined immunodeficiency associated with mutations in RGS10. Sci Signal. 2021;14(693).

  2. Matheny M, Maleque N, Channell N, Eisch AR, Auld SC, Banerji A, Druey KM. Severe Exacerbations of Systemic Capillary Leak Syndrome After COVID-19 Vaccination: A Case Series. Ann Intern Med. 2021.

  3. Cheung PC, Eisch AR, Maleque N, Polly DM, Auld SC, Druey KM. Fatal Exacerbations of Systemic Capillary Leak Syndrome Complicating Coronavirus Disease. Emerg Infect Dis. 2021;27(10).

  4. Wong GS, Redes JL, Balenga N, McCullough M, Fuentes N, Gokhale A, Koziol-White C, Jude JA, Madigan LA, Chan EC, Jester WH, Biardel S, Flamand N, Panettieri RA Jr, Druey KM. RGS4 promotes allergen- and aspirin-associated airway hyperresponsiveness by inhibiting PGE2 biosynthesis. J Allergy Clin Immunol. 2020;146(5):1152-1164.e13.

  5. Raza A, Xie Z, Chan EC, Chen WS, Scott LM, Robin Eisch A, Krementsov DN, Rosenberg HF, Parikh SM, Blankenhorn EP, Teuscher C, Druey KM. A natural mouse model reveals genetic determinants of systemic capillary leak syndrome (Clarkson disease). Commun Biol. 2019;2:398.


This page was last updated on August 17th, 2021